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Abstract
Purpose: To investigate whether EGF receptor (EGFR) pathway mutations
predicted response to monotherapy with panitumumab, an anti-EGFR
monoclonal antibody, in a randomized phase III study of metastatic colorectal
cancer. Experimental Design: Using massively parallel multigene sequencing, we
analyzed 320 samples for 9 genes, with multigene sequence data from 288 (90%)
samples. Results: Mutation rates were: KRAS (45%), NRAS (5%), BRAF (7%),
PIK3CA (9%), PTEN (6%), TP53 (60%), EGFR (1%), AKT1 (<1%), and CTNNB1
(2%). In the randomized study and open-label extension, 22 of 138 (16%) wild-
type KRAS (codons 12/13/61) patients versus 0 of 103 mutant KRAS (codons
12/13) patients had objective responses. Of 6 mutant KRAS (codon 61) patients,
1 with a Q61H mutation achieved partial response during the extension. Among
wild-type KRAS (codons 12/13/61) patients, 0 of 9 patients with NRAS mutations,
0 of 13 with BRAF mutations, 2 of 10 with PIK3CA mutations, 1 of 9 with PTEN
mutations, and 1 of 2 ...
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Abstract
Purpose: To investigate whether EGF receptor (EGFR) pathway mutations predicted response to
monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study
of metastatic colorectal cancer.
Experimental Design: Using massively parallel multigene sequencing, we analyzed 320 samples for 9
genes, with multigene sequence data from 288 (90%) samples.
Results: Mutation rates were: KRAS (45%), NRAS (5%), BRAF (7%), PIK3CA (9%), PTEN (6%), TP53
(60%), EGFR (1%), AKT1 (<1%), and CTNNB1 (2%). In the randomized study and open-label extension,
22 of 138 (16%) wild-type KRAS (codons 12/13/61) patients versus 0 of 103mutant KRAS (codons 12/13)
patients had objective responses. Of 6mutantKRAS (codon 61) patients, 1 with aQ61Hmutation achieved
partial response during the extension. Among wild-type KRAS (codons 12/13/61) patients, 0 of 9 patients
with NRAS mutations, 0 of 13 with BRAF mutations, 2 of 10 with PIK3CA mutations, 1 of 9 with PTEN
mutations, and 1 of 2 withCTNNB1mutations responded to panitumumab. No patients responded to best
supportive care alone. Panitumumab treatment was associated with longer progression-free survival (PFS)
among wild-type KRAS (codons 12/13/61) patients [HR, 0.39; 95% confidence interval (CI), 0.28–0.56].
Among wild-type KRAS patients, a treatment effect for PFS favoring panitumumab occurred in patients
withwild-typeNRAS (HR, 0.39; 95%CI, 0.27–0.56) andwild-typeBRAF (HR, 0.37; 95%CI, 0.24–0.55) but
not mutant NRAS (HR, 1.94; 95% CI, 0.44–8.44).
Conclusions: These results show the feasibility and potential clinical use of next-generation sequencing
for evaluating predictive biomarkers. Clin Cancer Res; 19(7); 1902–12. 2012 AACR.
Introduction
Improvements in progression-free survival (PFS) or
objective response rate (ORR) following treatment with the
anti–EGF receptor (EGFR) antibodies panitumumab and
cetuximab are confined to patients with wild-type KRAS
tumors as determined by allele-specific real-time PCR (1–
6). Current treatment guidelines recommend anti-EGFR
monoclonal antibodies for use only in patients with
wild-type KRAS (codons 12 and 13) colorectal tumors,
which are associated with lack of response to these agents
(7). However, not all patients with wild-type KRAS meta-
static colorectal cancer (mCRC) benefit from anti-EGFR
antibodies. In addition to KRAS mutations, multiple other
genes are known to be somatically mutated in mCRC and
have been assessed as biomarkers of response to anti-EGFR
therapy (8–13). Recent studies have suggested that muta-
tions in BRAF (8, 9, 13), as well asmutations in PI3KCA and
loss of PTEN expression (8, 9, 11–13), may be associated
with poor outcome in patients with mCRC treated with
agents targeting the EGFR. In a retrospective analysis of
tumor samples from patients with mCRC treated with
cetuximab plus chemotherapy, mutations in BRAF, NRAS,
and PIK3CA exon 20 were associated with low response
rates in patients with wild-type KRAS tumors (14). Con-
versely, mutations in the TP53 tumor suppressor gene have
been associated with favorable disease control and time to
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progression among patients treated with cetuximab plus
chemotherapy, including patients with wild-type KRAS
tumors (10). On the basis of these observations, the stron-
gest hypothesiswas that somaticmutations in theRAS genes
(KRAS and NRAS) beyond the KRAS codons 12 and 13
would be negatively predictive of response to panitumu-
mab. In addition, based on the existing literature, we pre-
dicted that activating mutations in BRAF and PIK3CA and
inactivating mutations in PTEN would be unfavorable in
the context of anti-EGFR therapy, whereas TP53mutations
would result in a favorable outcome.
We used massively parallel multigene sequencing techni-
ques (also known as next-generation sequencing) to analyze
3 types of alterations in parallel: additional RAS-activating
mutations (KRAS codon 61; NRAS codons 12/13/61), other
EGFRsignalingpathwaygenesknowntobemutated inmCRC
(EGFR, BRAF, PTEN, PIK3CA, and AKT), and genes known
to play a role in colorectal cancer (CRC) tumorigenesis and
progression (TP53 andCTNNB1).Massively parallel sequenc-
ing technology enables rapid and sensitive sequencing, thus
allowing the simultaneous identification of mutations from
multiple patient samples inmultiple genes potentially impor-
tant for tumor development (15, 16). The assessment was
conducted on banked tissue samples [formalin-fixed paraffin-
embedded (FFPE)] that were previously assessed for KRAS
codons 12 and 13 from patients with mCRC enrolled in a
randomized phase III study (the 408 study; ref. 17) and an
open-label extension study (the 194 study; ref. 18).
Patients and Methods
Patients
Samples were from patients with metastatic colorectal
adenocarcinoma enrolled in the randomized multicenter
phase III 408 study (Clinicaltrials.gov, NCT00113763;
ref. 17). Patients in the best supportive care (BSC) arm
of the randomized phase III study who had radiograph-
ically documented disease progression could enroll in the
open-label extension 194 study (Clinicaltrials.gov,
NCT00113776; ref. 18). The study protocol was approved
by independent ethics committees at each participating
center. Patients provided written informed consent.
Study design and treatment
Patients enrolled in the randomized phase III study (17)
from January 2004 to June 2005 were randomly assigned
1:1 to receive 2-week cycles of intravenous panitumumab
6 mg/kg every 2 weeks plus BSC or BSC alone. Median
follow-up time was 35 weeks. Randomization was stratified
by Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (0/1 vs. 2) and region [Western Europe
vs. Central/Eastern Europe vs. rest of the world (Canada,
Australia, and New Zealand)]. The primary endpoint was
PFS. Secondary endpoints included ORR per modified
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 (19) and overall survival (OS). Local and central
reviews were conducted for all assessments.
Patients from the BSC arm of the randomized phase III
studywhohad disease progression could enroll in the cross-
over extension study (18) and receive intravenous panitu-
mumab 6mg/kg every 2 weeks plus BSC. In February 2006,
median follow-up time was 61 weeks. The primary end-
point was safety. Exploratory endpoints included PFS, ORR
per modified RECIST version 1.0 (19), time to response,
duration of response, duration of stable disease, andOS, all
per local review.
Biomarker analysis
Archival CRC samples (all obtained from the patients
before trial initiation) were previously analyzed for KRAS
mutations (codons 12 and 13) using allele-specific PCR
(DxS/Qiagen; ref. 1). For this analysis, tumor DNA was
extracted from additional archival FFPE tissue sections
using the QIAmp DNA FFPE Tissue Kit (Qiagen). One
specimen per patient was analyzed. DNA isolates were
quantified using the Quant-iT PicoGreen dsDNA reagent
(Invitrogen). Slides representing the primary tumors of 324
patients were available for analysis. Two slides were avail-
able in most cases (n ¼ 308), but only a single slide was
available for 11 patients, and 3 ormore slideswere available
for 5 patients. Sequencing libraries were generated and used
in 454GS FLX (Roche 454 Life Sciences) sequencing experi-
ments. ThePCRprimers in this analysis targeted exons2 and
3 ofNRAS; exon 3 of KRAS; exon 2 of CTNNB1; exon 15 of
BRAF; exon 3 of AKT1; exons 1, 2, 9, 10, and 20 of PIK3CA;
exons 17 through 22 of EGFR; and all exons of PTEN and
TP53 (primer pair sequences are presented in Supplemen-
tary Table S1).
Up to 24 patient samples were interrogated per sequenc-
ing experiment. Amplified sequencing libraries were eval-
uated by capillary electrophoresis using the Agilent 2100
Bioanalyzer and DNA1000 Kit (Agilent Technologies, Inc.)
Translational Relevance
The anti–EGF receptor (EGFR) monoclonal antibo-
dies panitumumab and cetuximab are recommended for
the treatment of wild-type KRAS metastatic colorectal
cancer (mCRC), but not all patients withwild-typeKRAS
mCRC benefit from their treatment. Other genes have
been suggested as potential predictors of outcome in
patients treated with anti-EGFR monoclonal antibodies
for mCRC. Massively parallel multigene sequencing was
used to analyze mutations in KRAS,NRAS, EGFR, BRAF,
PTEN, PIK3CA, AKT, TP53, and CTNNB1 in tumor
samples from patients who received panitumumab in
a randomized phase III study or its open-label extension
study. Among wild-type KRAS patients, a treatment
effect for progression-free survival favoring panitumu-
mab occurred in patients with wild-typeNRAS andwild-
type BRAF but not mutant NRAS. The results of this
study, which was intended to generate hypotheses for
future prospective studies or meta-analyses, show the
feasibility and potential clinical use of next-generation
sequencing for evaluating predictive biomarkers.
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before sequencing. Libraries showing little or no amplifi-
cation of target amplicons, and/or a molar excess of non-
specific PCR artifact relative to target amplicons (again
using the Agilent 2100 Bioanalyzer and DNA1000 Kit),
were not used for sequencing. Sequence data were base-
called and filtered using default 454 GS FLX software set-
tings and further filtered to reject sequences that did not
contain 2 complete cognate locus-specific primer sequences
(i.e., the forward and reverse primer sequences for 1 of the
intended PCR amplicons). The latter filter prevented
sequences arising from PCR artifacts being included in data
used for mutation analysis.
Mutation analysis was carried out using the 454 Ampli-
conVariant Analysis (AVA) software version 2.0 (Roche 454
Life Sciences). Gene–subject combinations in which a
mutation was observed were assigned mutant status, and
wild-type statuswas assigned to gene–subject combinations
in which (i) no mutations were observed, and (ii) the
median number of sequence reads per amplicon for that
gene in that subject was more than 40. If no mutation was
observed but this second criterion was notmet, the status of
that gene–subject intersection was classified as "not deter-
mined." Some FFPEDNA samples, when amplified by PCR,
exhibit a sharply elevated frequency of artifactual transition
substitutions. To avoid making false-positive mutation
identifications in these cases, a metric of the severity of this
phenomenon was derived by counting the number of
nonreference bases present at each of 2,889 nucleotide
positions within the panel in which a substitution would
not alter the encoded polypeptide or disrupt a splice donor
or acceptor sequence and for which there was no reported
single-nucleotide polymorphism. Subsequently, a sample-
specific cutoff for acceptance of putative missense or non-
sense sequence variants was applied such that any variant
present in a smaller fractionof sequence reads than the third
most frequent "silent position" in a given sample was not
included (i.e., variants with approximately >0.1% proba-
bility of being an artifact). The sample-specific cutoff was
generally less than 5%.
The analysts conducting the assays were blinded to
clinical outcome data. The multigene sequencing assays
were extensively qualified to show the ability to confi-
dently detect mutations at a level of 5% of sequence reads
per amplicon using both cell line DNA and procured FFPE
colorectal tumor samples. Because of the nature of this
qualification, the demonstration of correlation between
this sequencing methodology and bidirectional sequenc-
ing (20), the lack of commercially available validated
assays for all of these mutations and the limiting amount
of material available for these samples, confirmation of
the mutation status using an additional method was not
pursued.
Statistical analysis
The analysis included all intent-to-treat patients with
available biomarker information. The statistical analysis
plan was developed before analyses were conducted. As
specified in the analysis plan, patient data were analyzed on
the basis of randomized treatment assignment (regardless
of actual treatment administered).
Assessment of gene frequency
Genotype frequencywas calculated for eachbiomarker by
treatment arm and by overall frequency.
Evaluation of treatment effect on PFS in the
randomized study
In the randomized phase III study, the treatment effect on
PFS (independent blinded radiologic review) of panitumu-
mab plus BSC versus BSC for all evaluable patients and the
wild-type KRAS subgroup was estimated by genotype using
a Cox proportional hazards model adjusted for the ran-
domization factors.
Evaluation of biomarker effect on PFS in the
randomized study
The relative biomarker effect (mutant vs. wild-type) with-
in each treatment arm (panitumumab plus BSC, BSC only,
and total) was evaluated using a Cox proportional hazards
model adjusted for the randomization factors.
Analysis of the randomized study and the extension
studies combined
This analysis included patients enrolled in the panitu-
mumab plus BSC arm of the randomized phase III study
and in the open-label extension study. The analysis was
conducted for each study and for both studies combined,
for all evaluable patients, and within the wild-type KRAS
subgroup. For the combined analyses, the patients enrolled
in the extension study were considered equivalent to
patients randomized to panitumumab in the phase III
study. Because the extension study was reviewed locally,
ORRandPFSbasedon local reviewwereused for analyses of
the randomized study and the extension study.
PFS was defined as time from the date of enrollment to
disease progression or death. Patients who had not pro-
gressed or died during the study were censored at the last
evaluable disease assessment date. For the panitumumab
plus BSC arm in the randomized phase III study, the initial
enrollment date was used. For patients in the extension
study, enrollment date into the extension study was used.
Because the key eligibility criteria for the extension study
was disease progression in the randomized study, by def-
inition, patients in the extension study already had one
disease progression before entering the extension study.
ORR and 95% confidence intervals (CI) were calculated
for each biomarker by genotype and by study: the panitu-
mumab plus BSC arm in the randomized study, the exten-
sion study, and both combined. Cox proportional hazard
models adjusted for the randomization factors ECOG score
and demographic region were used to estimate the effect of
mutant versus wild-type of each biomarker on PFS under
the panitumumab plus BSC treatment. For these explorato-
ry analyses, the reported P values are presented for descrip-
tive purposes only. P values near or less than 0.05 are
believed to show potential for further investigation (i.e.,
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for hypothesis generation). No adjustments for multiple
comparisons were made with the reported P values.
Results
Patients
As previously reported, 463 patients were randomized
to panitumumab 6 mg/kg every 2 weeks plus BSC (n ¼
231) or BSC alone (n ¼ 232) in the phase III study (study
20020408); 176 patients (76%) from the BSC arm with
progressive disease enrolled in the optional extension
study (study 20030194) of panitumumab monotherapy
(Fig. 1; refs. 17, 18). In the randomized study, PFS was
improved with panitumumab compared with BSC alone
(HR, 0.54; 95% CI, 0.44–0.66; P < 0.0001; ref. 17). The
treatment effect of panitumumab was greater (P < 0.0001)
among patients with wild-type KRAS codons 12 and 13
(HR, 0.45; 95% CI, 0.34–0.59) than among those with
KRAS mutations (HR, 0.99; 95% CI, 0.73–1.36; ref. 1).
The ORR among patients with wild-type KRAS (codons
12/13) who were randomized to panitumumab was 17%
(95% CI, 11%–25%); no responses occurred among
patients with KRAS mutations (1). No significant differ-
ence in OS was observed between the treatment arms in
the randomized study (HR, 1.00; 95% CI, 0.82–1.22; P ¼
0.81) and KRAS status was not predictive for OS (1, 17),
perhaps because 76% of patients from the BSC arm
received panitumumab in the extension study.
Gene mutation analysis
Overall, 320 archival FFPE tumor samples were available
from the 463 patients in the 20020408 study, 288 (288 of
320; 90%) of which (panitumumab, n ¼ 147; BSC, n ¼
141; Fig. 1) provided information for multiple genes.
Demographic and clinical characteristics for patients with
or without multigene information were generally similar;
patients from Western Europe were more likely to have
available multigene information (Supplementary Table
S2). Among the 141 patients randomized to the BSC arm
with samples, 110 were enrolled in the panitumumab
extension study. Forty-nine primer pairs were used to
amplify 41 exons, resulting in 5.7  106 DNA sequence
reads, comprising 1.26  109 base pairs. Estimated total
tissue volume [area (number of slides) 0.005] used for
DNA isolation ranged from less than 0.1 to more than 9
mm3 (mean, 3.1 mm3), and the quantity of DNA recovered
ranged from0.1 to 5.37mg (mean, 1.19mg). Consistentwith
studies that have shown amplification of KRAS sequences
from small quantities of FFPE tissue (21), there was only a
weak relationship between amount of tissue processed and
DNA yield (R2 ¼ 0.16).
N = 1,040
III p
p
III
n = 463
n = 231
n = 147
n = 82 n = 65
n = 232
n = 141
n = 71 n = 70
n = 176
n = 110
n = 54n = 56
Figure 1. CONSORT diagram. Q2W, every 2 weeks.
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Mutation rates and data completeness for each of the
genes analyzed (KRAS,NRAS, EGFR, BRAF, PTEN, PIK3CA,
AKT1, TP53, and CTNNB1) are shown in Table 1 and
mutations identified for individual patients are shown in
Supplementary Table S3. Overall, 124 of 277 (45%)
patientswith available data had amutation inKRAS, among
whom 117 had mutations in KRAS codons 12 or 13, and 7
had mutations in KRAS codon 61. Five percent of patients
had mutations in NRAS and 7% had mutations in BRAF.
Sequencing identified 109 tumors with mutations in more
than 1 gene and 20 tumors with more than 1 mutation in a
single gene. Three tumors were identified withmutations in
KRAS (codons 12/13/61) and NRAS, and 2 tumors were
identified withmutations in both KRAS (codons 12/13/61)
and BRAF (Table 2). Most patients with 2 or more mutant
genes had a TP53mutation and amutation at another locus
(or 2 other loci). Dual mutations in genes other than TP53
were observed in several patients.
Table 1. Mutation rates in patient tumor specimens available for analysis (N ¼ 288)
Gene
Mutation
rate, %
Patients with
mutations, n
Patients with data
available, n
Data
completenessa, %
KRAS (codons 12, 13, and 61) 45 124 277 96
KRAS (codons 12 and 13)b 42 117 280 97
KRAS (codon 61) 2 7 284 99
NRAS 5 14 282 98
EGFR 1 3 280 97
BRAF 7 18 243 84
PTEN 6 15 272 94
PIK3CA 9 24 255 89
AKT1 <1 1 250 87
TP53 60 167 277 96
CTNNB1 2 5 256 89
NOTE: AKT1, v-akt murine thymoma viral oncogene homolog 1; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CTNNB1,
catenin (cadherin-associated protein), b-1, 88 kDa; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NRAS, neuroblas-
toma RAS viral oncogene homolog; PIK3CA, phosphoinositide-3-kinase, catalytic, a-polypeptide; PTEN, phosphatase and tensin
homolog; TP53, tumor protein p53.
aFor each gene, data completeness assessed as the number of patients with data available divided by 288 (the number of patients with
samples yielding results).
bData from a previous analysis of KRAS mutations (codons 12 and 13) using allele-speciﬁc polymerase chain reaction (DxS/Qiagen;
ref. 1).
Table 2. Joint frequencydistributionofmutations across all genepairs inpatient tumor specimensavailable
for analysis (N ¼ 288)
Gene, n
AKT1,
n ¼ 1
BRAF,
n ¼ 18
CTNNB1,
n ¼ 5
EGFR,
n ¼ 3
KRAS,
n ¼ 124
NRAS,
n ¼ 14
PIK3CA,
n ¼ 24
PTEN,
n ¼ 15
TP53,
n ¼ 167
AKT1
BRAF 1
CTNNB1 — —
EGFR — — —
KRASa — 2 1 3
NRAS — – — — 3
PIK3CA — 2 1 — 13 —
PTEN — 4 — 1 6 1 1
TP53 — 8 1 1 66 9 12 9
NOTE: AKT1, v-akt murine thymoma viral oncogene homolog 1; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CTNNB1,
catenin (cadherin-associated protein), b-1, 88 kDa; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NRAS, neuroblas-
toma RAS viral oncogene homolog; PIK3CA, phosphoinositide-3-kinase, catalytic, a-polypeptide; PTEN, phosphatase and tensin
homolog; TP53, tumor protein p53.
aKRAS mutations in codons 12, 13, or 61.
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Association between gene mutations and PFS among
patients with wild-type KRAS in the randomized study
The effect of panitumumab treatment on PFS (indepen-
dent blinded radiologic review) for each genotype in
patients with wild-type KRAS from the randomized study
is shown in Fig. 2. Among patients with wild-type KRAS
(codons 12/13/61) and wild-type NRAS (n ¼ 138), treat-
ment with panitumumab was associated with improved
PFS (HR, 0.39; 95% CI, 0.27–0.56; P < 0.001), but in
patients with wild-type KRAS (codons 12/13/61) and
mutant NRAS (n ¼ 11), treatment with panitumumab
was not associated with longer PFS (HR, 1.94; 95% CI,
0.44–8.44; P ¼ 0.379). Among wild-type KRAS patients, a
Cox proportional hazards model with NRAS, treatment,
and their interaction showed P ¼ 0.076 for the interaction
term, which was suggestive of an interaction. However,
the presence of BRAF mutations among patients with
wild-type KRAS did not seem to predict the effect of treat-
ment with panitumumab on PFS. A favorable effect of
panitumumab on PFS was observed in patients with
wild-type BRAF (n ¼ 115; HR, 0.37; 95% CI, 0.24–0.55;
P < 0.001) and potentially in patients with BRAF muta-
tions (n ¼ 15; HR, 0.34; 95% CI, 0.09–1.24; P ¼ 0.104).
Similarly, a favorable effect of panitumumab on PFS was
Gene Genotype HR 95% CI P valueN
KRAS WT
NRAS
EGFR
BRAF
PTEN
PIK3CA
AKT1
TP53
CTNNB1
Total
WT
MT
ND
WT
MT
ND
WT
MT
ND
WT
MT
ND
WT
MT
ND
WT
MT
ND
WT
MT
ND
WT
MT
ND
153
138
11
4
149
0
4
115
15
23
135
9
9
128
10
15
133
1
19
56
93
4
132
3
18
0.39
0.39
1.94
0.00
0.40
NE
NE
0.37
0.34
0.32
0.36
0.11
1.34
0.39
0.15
0.50
0.35
NE
0.70
0.33
0.38
1.21
0.44
0.00
0.09
0.28–0.56
0.27–0.56
0.44–8.44
0.00–NE
0.28–0.58
NE
NE
0.24–0.55
0.09–1.24
0.12–0.85
0.25–0.52
0.01–1.52
0.26–6.85
0.26–0.57
0.01–1.57
0.12–2.00
0.24–0.51
NE
0.23–2.13
0.18–0.63
0.24–0.60
0.07–19.71
0.30–0.64
0.00–NE
0.02–0.43
<0.0001
<0.0001
0.3789
1.0000
<0.0001
NE
NE
<0.0001
0.1035
0.0223
<0.0001
0.1001
0.7290
<0.0001
0.1139
0.3254
<0.0001
NE
0.5346
0.0006
<0.0001
0.8957
<0.0001
0.9990
0.0026
Pmab BSC
0.001 0.01 0.1 1.0 10.0 100.0
Favors
HR (Pmab/BSC)
Figure 2. HRs for the relative risk of PFS in the KRASwild-type subgroup for panitumumab plus BSC versus BSC alone. MT, mutant; ND, not determined; NE,
not evaluable; Pmab, panitumumab; WT, wild-type.
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observed in patients with wild-type PTEN (n ¼ 135; HR,
0.36; 95% CI, 0.25–0.52; P < 0.001) and in patients
with wild-type PIK3CA (n ¼ 128; HR, 0.39; 95% CI,
0.26–0.57; P < 0.001). Trends toward improved PFS among
patients randomized to panitumumab were observed for
patients with PTEN mutations (n ¼ 9; HR, 0.11; 95% CI,
0.01–1.52; P ¼ 0.100) and in patients with PIK3CA muta-
tions (n¼ 10;HR, 0.15; 95%CI, 0.01–1.57; P¼ 0.114). Cox
proportional hazard models similar to those described
earlier for NRAS were conducted for BRAF, PTEN, and
PIK3CA. In each case, the interaction terms did not suggest
statistical significance (BRAF, P ¼ 0.850; PTEN, P ¼ 0.771;
PIK3CA, P ¼ 0.616).
Among patients with wild-type KRAS from the random-
ized study, the presence of BRAF mutations was associated
with poor PFS regardless of treatment. Among patients with
BRAFmutations, theHR for PFS formutant versuswild-type
status was 2.55 (95% CI, 1.04–6.24) in the BSC arm, 3.27
(95% CI, 1.52–7.01) in the panitumumab plus BSC arm,
and 2.39 (95% CI, 1.36–4.21) overall (Fig. 3). No other
gene mutation among patients with wild-type KRAS was
negatively prognostic for PFS.
Association between gene mutations and objective
response among panitumumab-treated patients with
wild-type KRAS in the randomized and extension
studies
The sample size was increased by examining the ORR in
patients treated with panitumumab monotherapy in both
the randomized and the extension studies. ORR was 16%
for patients with wild-type KRAS (n¼ 138) versus 1% with
mutant-type KRAS (codons 12/13/61; n ¼ 109). One
patient with a KRASQ61Hmutation had a partial response
(local review) while receiving panitumumab in the exten-
sion study. Fifty-eight percent of this patient’s KRAS codon
61 sequencing reads were Q61H. Furthermore, a mutation
in TP53was detected in this patient’s sample; all other genes
examined were wild-type.
ORRs for wild-type versus mutant genotypes among
patients with wild-type KRAS (codons 12/13/61) who were
randomized to panitumumab in the randomized study or
the extension study are summarized in Table 3 and the
Supplementary Figure. Among 126 patients with wild-type
KRAS (codons 12/13/61) andNRAS, 22 achieved objective
responses with an ORR of 17% (95% CI, 0.11–0.25).
Among 98 patients with wild-type KRAS,NRAS, and BRAF,
18 achieved objective responses with an ORR of 18% (95%
CI, 0.11–0.27). No responses to panitumumab occurred in
patients with wild-type KRAS and mutations in NRAS or
BRAF (0 of 22 patients; 95% CI, 0–0.15). No patients
responded to BSC alone.
Discussion
To our knowledge, this is the first use of next-genera-
tion sequencing to assess potential predictive biomarkers
of response using tumor samples from a randomized
phase III clinical trial. Previous reports described the use
of massively parallel pyrosequencing techniques to inves-
tigate disease markers only in small patient populations
(22–24).
In this retrospective analysis designed to explore
effects of tumor genotype on outcomes, we were able
to show trends and develop hypotheses; however, con-
fidence of the observed trends was somewhat limited by
the low prevalence of many of the gene mutations. For
example, BRAF is mutated in approximately 10% of
patients with mCRC. In this study, the treatment HR or
effect size was calculated to be 0.34 (95% CI, 0.09–1.24),
similar to that of wild-type KRAS. Using this HR, 46
specimens that are KRAS wild-type and BRAF mutant
would be required to achieve 90% power with 2-sided
type I error set to 0.05. For the KRAS wild-type/NRAS-
mutant population, given an HR of 1.94 (95% CI, 0.44–
8.44), we estimate that 129 patients with this genotype
would be required to provide 90% power. Given these
Favors the mutant
genotype group
No difference
in hazard
Favors the wild
genotype group
0.01 0.1 0.0 10.0 100.0
Gene Treatment
Wild- 
type HR 95% CI P value
BRAF BSC
BSC + Pmab
Total
52
63
115
6
9
15
2.551
3.265
2.389
1.04–6.24
1.52–7.01
1.36–4.21
0.0401
0.0024
0.0026
Mutant 
Figure 3. HRs for the relative risk of PFS with panitumumab therapy in the KRASwild-type subgroup for wild-type versus mutant genotype in the randomized
phase III and extension studies combined. Pmab, panitumumab.
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limitations, hypothesis testing of these low prevalence
genes will likely require carefully constructed meta-anal-
yses. The use of multiplexed, multigene analysis is a
useful tool for hypothesis generation in translational
studies.
The frequency of gene mutations observed in this study
with 5% sensitivity is generally consistent with mutation
rates for adenocarcinoma of the colon or rectum published
in the Catalogue of Somatic Mutations in Cancer database
(25) and with those reported by Vaughn and colleagues
(26). The consistencyof our resultswithpreviously reported
studies suggests that the data are reliable.
Consistent with other reports of anti-EGFR antibodies in
mCRC (1–3, 6, 14, 27), objective responses to panitumu-
mabwere confined to patients withwild-typeKRAS tumors.
Interestingly, 1 patient with a codon 61 mutation (Q61H)
had a partial response per local review. Prior analyses of
KRASmutational status in anti-EGFRmonoclonal antibody
therapy have primarily assessed mutations only in codons
12and13 (1, 3, 6, 14, 27); however, 1 study reported that no
patients with mutations in codon 61 (n ¼ 8) responded to
treatment with cetuximab plus irinotecan (28). We did not
assess thepredictive or prognostic valueof individual codon
12/13 mutations but a recent pooled analysis of 3 random-
ized phase III studies of panitumumab in mCRC (which
included patients from the randomized phase III 408
study), found that no individual mutant KRAS allele was
consistently associated with PFS or OS outcomes (29).
Conversely, pooled analyses of clinical trials in which
cetuximab was administered as a component of first-line
chemotherapy (30) or in chemotherapy-refractory disease
(31) have suggested that patients with colorectal tumors
bearing KRAS G13D mutations have favorable outcomes
versus patients with other KRAS mutations.
Our data are consistent with the hypothesis that NRAS
mutations, which occur infrequently (<5%) in mCRC
(14, 25, 26, 32, 33),may limit the efficacy of panitumumab.
In patients with wild-type KRAS and mutant NRAS tumors
assigned to panitumumab therapy in either the randomized
or extension study (n ¼ 9), there was a lack of response
(Table 3) and a lack of improved PFS (HR for mutant vs.
wild-type, 1.71; 95% CI, 0.81–3.62). As described earlier,
because mutations in NRAS are low-prevalence mutations,
their true predictive or prognostic value must be confirmed
in larger studies.
The negative prognostic effect of BRAF is clearly seen for
PFS (Fig. 3). Because no patients responded in the BSC arm
of the randomized study, evaluationof its prognostic poten-
tial forORR is difficult. However, the negative effect ofBRAF
mutation was clearly seen in the treatment arm within the
Table 3. Response rates of patients with wild-type KRAS (codons 12/13/61) who were randomized to
panitumumab plus BSCa
Randomized phase III study
panitumumab þ BSC
Extension study
panitumumab þ BSC
Combined
panitumumab þ BSC
n ¼ 82 n ¼ 56 n ¼ 138
Genotype n
Response
rate, % (95% CI) n
Response
rate, % (95% CI) n
Response
rate, % (95% CI)
NRAS WT 76 13 (6–23) 50 24 (13–38) 126 17 (11–25)
MT 4 0 (0–60) 5 0 (0–52) 9 0 (0–34)
EGFR WT 82 12 (6–21) 52 23 (13–37) 134 16 (11–24)
MT 0 NA 0 NA 0 NA
BRAF WT 63 14 (7–25) 44 21 (10–35) 107 17 (10–25)
MT 9 0 (0–34) 4 0 (0–60) 13 0 (0–25)
PTEN WT 72 13 (6–22) 50 22 (12–36) 122 16 (10–24)
MT 7 14 (0–58) 2 0 (0–84) 9 11 (0–48)
PIK3CA WT 74 12 (6–22) 43 19 (8–33) 117 15 (9–22)
MT 5 20 (1–72) 5 20 (1–72) 10 20 (3–56)
AKT1 WT 69 15 (7–25) 52 19 (10–33) 121 17 (10–24)
MT 1 0 (0–98) 0 NA 1 0 (0–98)
TP53 WT 32 16 (5–33) 18 11 (1–35) 50 14 (6–27)
MT 49 10 (3–22) 35 26 (13–43) 84 17 (9–26)
CTNNB1 WT 72 11 (5–21) 46 22 (11–36) 118 15 (9–23)
MT 2 50 (1–99) 0 NA 2 50 (1–99)
NOTE: AKT1, v-akt murine thymoma viral oncogene homolog 1; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CTNNB1,
catenin (cadherin-associatedprotein),b-1, 88 kDa;MT,mutant;NA, not available;NRAS, neuroblastomaRASviral oncogenehomolog;
PIK3CA, phosphoinositide-3-kinase, catalytic,a-polypeptide;PTEN, phosphatase and tensin homolog; TP53, tumor protein p53;WT,
wild-type.
aPer local review.
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KRASwild-type population, in which the response rate was
17%with wild-type BRAF compared with no response with
mutant BRAF. In addition, there is ample evidence that
BRAF mutations may have use as a prognostic marker in
mCRC (14, 34–38). In this analysis, it is unknown whether
the observed dual mutations in KRAS and BRAF arose from
tumor heterogeneity (i.e., different cell populations within
the tumor) or the presence of both mutations within indi-
vidual tumor cells. The use of techniques capable of dis-
crimination at the single-cell level will be required to
address this question.
Our results do not support the hypothesis that PIK3CA or
PTENmutations are negative predictivemarkers as has been
suggested by the work of Sartore-Bianchi and colleagues
(39). In the randomized and extension studies, 18 patients
with wild-type KRAS (codons 12/13/61) treated with pani-
tumumab monotherapy had PIK3CA and/or PTEN muta-
tions, and of these, 3 patients (PTEN mutation, n ¼ 1;
PIK3CA mutation, n ¼ 2) achieved a partial response. In
addition, 1 of these 3 patients had an exon 20 PIK3CA
mutation. Our observations are not consistent with the
hypothesis that exon 20 PIK3CA mutations (but not exon
9 PIK3CA mutations) predict response to treatment with
anti-EGFR monoclonal antibodies (14). De Roock and
colleagues previously reported that although PIK3CA exon
9 mutations did not influence outcomes among patients
receiving cetuximab-based chemotherapy for mCRC, exon
20 mutations were associated with a lower response rate
(0% vs. 37% for wild-type PIK3CA; P ¼ 0.029) and disease
control rate (33% vs. 76%; P ¼ 0.0078), as well as shorter
medianPFS (11.5 vs. 24weeks;P¼0.013) andOS (34 vs. 51
weeks; P ¼ 0.0057). However, it is possible that our results
may have been affected by the smaller number of patients
with PIK3CA data evaluable for response in the phase III
study (n¼ 79) and extension study (n¼ 48) compared with
the De Roock and colleagues analysis (n¼ 339). Although,
we found favorable effects of panitumumab on PFS in
patients with wild-type and mutant PTEN and PIK3CA, our
results should be interpreted with caution given the small
number of patients with these mutations. This exploratory
analysis suggests that other mutated genes within the EGFR
signaling pathway do not seem to confer the same strictly
negative predictive value for response to anti-EGFR anti-
body therapy that specific mutations in the RAS family
genes (KRAS and NRAS) seem to confer.
Future meta-analyses would ideally use the same well-
established methodology to ensure confidence and con-
sistency in the wild-type and mutation assignments. This
is especially important due to the varying tumor content
of each tissue section, as well as the potential for hetero-
geneity within tumor cells of the individual tissue section.
It should be noted that when more than 1 mutation is
present in a tissue section extract, the percentage of
mutant sequence reads is not always the same across the
different amplimers, thus reflecting either aneuploidy of
the different gene segments or tumor cell heterogeneity
(data not shown). It should also be noted that we did not
confirm mutations using a second analytic technique.
However, in a separate comparability study, we found
assessment of KRAS status using Roche 454 pyrosequen-
cing to have a high level of agreement (k ¼ 0.94) with
direct sequencing (20).
In summary, although only KRAS mutational status
predicted response to treatment with panitumumab,
among patients with wild-type KRAS, objective responses
did not occur in patients with mutations in NRAS or
BRAF. Because of the relatively limited frequencies of
mutations in KRAS codon 61 and NRAS codons 12/13/
61, a large prospective analysis of these biomarkers will
be difficult to conduct. However, because these results
show the use of retrospective analysis of tumor speci-
mens using massively parallel multigene sequencing, a
pooled analysis of gene mutations in the RAS family is
warranted.
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